Lasa Supergenerics Appoints Ganesh Suresh Potdar as Executive Director
Lasa Supergenerics Limited's Board of Directors approved the appointment of Mr. Ganesh Suresh Potdar as an Additional Director in the capacity of Executive Director. This appointment is effective from January 02, 2026, to January 01, 2030, and requires member approval. Mr. Potdar brings expertise in business operations and banking processes.
The appointment of an Executive Director can have a medium-term impact on the company's strategic direction and operational management.
The announcement is a routine corporate action regarding the appointment of a director and does not contain any immediately positive or negative financial or operational news.
Lasa Supergenerics Limited announced the outcome of its Board Meeting held on January 02, 2026. The board approved the appointment of Mr. Ganesh Suresh Potdar as an Additional Director in the capacity of Executive Director and Occupier of all units of the company.
This appointment is subject to the approval of the company's members, which will be sought through an ensuing General Meeting or Postal Ballot. Mr. Potdar, born on February 27, 1975, is an Indian national with undergraduate qualifications. His expertise lies in business operations, commercial practices, and banking-related processes, including coordination with financial institutions and documentation compliance.
The appointment is for a term from January 02, 2026, to January 01, 2030. Mr. Potdar currently holds no directorships in other public companies, nor is he a member or chairman of any audit or stakeholder committees in public companies. He holds no shares in Lasa Supergenerics Limited. The board meeting commenced at 2:00 p.m. and concluded at 4:00 p.m. on January 02, 2026.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.